fashion -WSS

fashion

author：knowledge 2025-10-02 09:47:20 - browse：44

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Shingles, which affected Dianne Feinstein, is on the rise

explore

WSS

Why do women spend more than men on medical expenses?

Maui wildfire now ranks as the fifth

Mindstrong's demise and the future of mental health care

How one patient went off dialysis — and others can too

BMS, looking to build heart drug business, turns to AI for diagnosis

Medicare drug price negotiation program allowed for now

explore

fashion

explore

Medical records are filled with copy

FDA advisers vote against ALS treatment from BrainStorm

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Indictment alleges Trump's ex

ChatGPT in medicine: STAT answers readers' burning questions

Be careful with at

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Bird flu researchers hone in on Finland’s mink farms

Duchenne breakthrough therapy leaves behind pioneering families

Medicaid, Medicare dual

focus

Intercept Pharmaceuticals sells itself for less than $1 billion

Dozens dead from Maui wildfires: What we know about the victims

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Covid vaccines: Private market messier than government rollout

Aspartame and sugar

Biogen shutters digital health group, ends Apple study, in cost cutting move

Wikipedia

knowledge

entertainment

entertainment